HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy
Menée à partir de données portant sur 179 520 patients atteints d'un lymphome sur la période 2004-2011, cette étude évalue les effets d'une infection par le VIH et d'un traitement antirétroviral hautement actif sur la survie
Résumé en anglais
Background: Highly active antiretroviral therapy (HAART) has extended the life expectancy of patients with HIV/AIDS to approach that of the general population. However, it remains unclear whether HIV infection affects the survival of patients with lymphoma in the HAART era.
Methods: Patients diagnosed with Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, peripheral T-cell lymphoma (PTCL), or follicular lymphoma during 2004–2011 were identified from the National Cancer Database. Survival analyses were conducted, where each HIV-infected patient was propensity score matched to a HIV-uninfected patient on the basis of demographic factors, clinical features, and treatment characteristics.
Results: Among 179,520 patients, the prevalence of HIV-infection ranged from 1.0% for follicular lymphoma, 3.3% for PTCL, 4.7% for Hodgkin lymphoma, 5.4% for DLBCL, to 29% for Burkitt lymphoma. HIV infection was significantly associated with inferior overall survival for patients with each lymphoma subtype: Hodgkin lymphoma [HR, 1.47; 95% confidence interval (CI), 1.25–1.74], DLBCL (HR, 1.95; 95% CI, 1.80–2.11), Burkitt lymphoma (HR, 1.46; 95% CI, 1.24–1.73), PTCL (HR, 1.43; 95% CI, 1.14–1.79), and follicular lymphoma (HR, 1.44; 95% CI, 1.04–2.00).
Conclusions: HIV/AIDS continues to be independently associated with increased risk of death among patients with lymphoma in the HAART era in the United States, and the association varies by lymphoma histologic subtype.
Impact: Examination of effective management strategies for patients with HIV/AIDS-associated lymphoma and enrollment of patients in prospective clinical trials are needed to improve patient outcomes. Cancer Epidemiol Biomarkers Prev; 26(3); 1–9. ©2016 AACR.%U
